Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer|PI3K/AKT/mTOR Pathway Mutation|Everolimus
Interventions: OTHER: No intervention, it was a retrospective study.
Sponsor: Zhejiang Cancer Hospital